Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

Hiddo J Lambers Heerspink; Misghina Weldegiorgis; Lesley A Inker; Ron Gansevoort; Hans-Henrik Parving; Jamie P Dwyer; Hasi Mondal; Josef Coresh; Tom Greene; Andrew S Levey; Dick de Zeeuw

doi:10.1053/j.ajkd.2013.09.016

Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

Hiddo J Lambers Heerspink, Misghina Weldegiorgis, Lesley A Inker, Ron Gansevoort, Hans-Henrik Parving, Jamie P Dwyer, Hasi Mondal, Josef Coresh, Tom Greene, Andrew S Levey, Dick de Zeeuw

67 Citationer (Scopus)

Abstract

A doubling of serum creatinine value, corresponding to a 57% decline in estimated glomerular filtration rate (eGFR), is used frequently as a component of a composite kidney end point in clinical trials in type 2 diabetes. The aim of this study was to determine whether alternative end points defined by smaller declines in eGFR would improve the statistical power of these clinical trials.

Originalsprog	Engelsk
Tidsskrift	American journal of kidney diseases : the official journal of the National Kidney Foundation
Vol/bind	63
Udgave nummer	2
Sider (fra-til)	244-50
ISSN	0272-6386
DOI	https://doi.org/10.1053/j.ajkd.2013.09.016
Status	Udgivet - 2014

Adgang til dokumentet

10.1053/j.ajkd.2013.09.016

Fingeraftryk

Dyk ned i forskningsemnerne om 'Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Lambers Heerspink, H. J., Weldegiorgis, M., Inker, L. A., Gansevoort, R., Parving, H.-H., Dwyer, J. P., Mondal, H., Coresh, J., Greene, T., Levey, A. S., & de Zeeuw, D. (2014). Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American journal of kidney diseases : the official journal of the National Kidney Foundation, 63(2), 244-50. https://doi.org/10.1053/j.ajkd.2013.09.016

Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). / Lambers Heerspink, Hiddo J; Weldegiorgis, Misghina; Inker, Lesley A et al.
I: American journal of kidney diseases : the official journal of the National Kidney Foundation, Bind 63, Nr. 2, 2014, s. 244-50.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Lambers Heerspink, HJ, Weldegiorgis, M, Inker, LA, Gansevoort, R, Parving, H-H, Dwyer, JP, Mondal, H, Coresh, J, Greene, T, Levey, AS & de Zeeuw, D 2014, 'Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)', American journal of kidney diseases : the official journal of the National Kidney Foundation, bind 63, nr. 2, s. 244-50. https://doi.org/10.1053/j.ajkd.2013.09.016

Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP et al. Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;63(2):244-50. doi: 10.1053/j.ajkd.2013.09.016

Lambers Heerspink, Hiddo J ; Weldegiorgis, Misghina ; Inker, Lesley A et al. / Estimated GFR Decline as a Surrogate End Point for Kidney Failure : A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). I: American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014 ; Bind 63, Nr. 2. s. 244-50.

@article{895eb1d7bb9e4ed19d7727ba86e93088,

title = "Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)",

abstract = "A doubling of serum creatinine value, corresponding to a 57% decline in estimated glomerular filtration rate (eGFR), is used frequently as a component of a composite kidney end point in clinical trials in type 2 diabetes. The aim of this study was to determine whether alternative end points defined by smaller declines in eGFR would improve the statistical power of these clinical trials.",

author = "{Lambers Heerspink}, {Hiddo J} and Misghina Weldegiorgis and Inker, {Lesley A} and Ron Gansevoort and Hans-Henrik Parving and Dwyer, {Jamie P} and Hasi Mondal and Josef Coresh and Tom Greene and Levey, {Andrew S} and {de Zeeuw}, Dick",

year = "2014",

doi = "10.1053/j.ajkd.2013.09.016",

language = "English",

volume = "63",

pages = "244--50",

journal = "American journal of kidney diseases : the official journal of the National Kidney Foundation",

issn = "0272-6386",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Estimated GFR Decline as a Surrogate End Point for Kidney Failure

T2 - A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

AU - Lambers Heerspink, Hiddo J

AU - Weldegiorgis, Misghina

AU - Inker, Lesley A

AU - Gansevoort, Ron

AU - Parving, Hans-Henrik

AU - Dwyer, Jamie P

AU - Mondal, Hasi

AU - Coresh, Josef

AU - Greene, Tom

AU - Levey, Andrew S

AU - de Zeeuw, Dick

PY - 2014

Y1 - 2014

N2 - A doubling of serum creatinine value, corresponding to a 57% decline in estimated glomerular filtration rate (eGFR), is used frequently as a component of a composite kidney end point in clinical trials in type 2 diabetes. The aim of this study was to determine whether alternative end points defined by smaller declines in eGFR would improve the statistical power of these clinical trials.

AB - A doubling of serum creatinine value, corresponding to a 57% decline in estimated glomerular filtration rate (eGFR), is used frequently as a component of a composite kidney end point in clinical trials in type 2 diabetes. The aim of this study was to determine whether alternative end points defined by smaller declines in eGFR would improve the statistical power of these clinical trials.

U2 - 10.1053/j.ajkd.2013.09.016

DO - 10.1053/j.ajkd.2013.09.016

M3 - Journal article

C2 - 24210590

SN - 0272-6386

VL - 63

SP - 244

EP - 250

JO - American journal of kidney diseases : the official journal of the National Kidney Foundation

JF - American journal of kidney diseases : the official journal of the National Kidney Foundation

IS - 2

ER -